logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Opening the door to first-line immunotherapy in advanced gastroesophageal cancers

Nivolumab plus chemotherapy has superior survival effect vs chemotherapy alone.